Table 4.

Immune checkpoint inhibitors based on American Society of Clinical Oncology's meeting abstracts

Target molecule	Drug name	Study phase	Study design	Status	Condition	Intervention	Cohort	Estimated enrollment	Dose	End point	Study Arm	Adverse event	Response	Survival	Ref.
CTLA-4	Tremelimumab	1	Non-randomized	Recruiting	PC	Palliative	Metastatic	60	NA	Safety	Durvalumab, SBRT (Arm A)	NA	NA	NA	Duffy et al[28]
	(CP-675/CP-675,206)									Efficacy (ORR, PFS)	Tremelimumab, SBRT (Arm B)
										Tolerability	Durvalumab, Tremelimumab, SBRT (Arm C)
										PK
PD-1	Nivolumab	2	Randomized	Recruiting	PC	Palliative	Metastatic	94	3 mg/kg	Safety (TRT)	Cy/GVAX/Nivolumab, CRS-207/Nivolumab (Arm A)	NA	NA	NA	Le et al[25]
	(BMS-936558/MDX-1106/ONO-4538)									Efficacy (OS, PFS, RR)	Cy/GVAX, CRS-207 (Arm B)
		1	Randomized	Recruiting	PC, NSCLC, BC	Palliative	Locally advanced	138	3 mg/kg	Safety (DLT, TEAEs)	Nivolumab, nab-Paclitaxel (Arm A)	NA	NA	NA	Firdaus et al[45]
							Metastatic			Efficacy (PFS, OS, DCR, ORR, DR)	Nivolumab, nab-Paclitaxel, Gemcitabine (Arm B)
	Pembrolizumab	1|2	Non-randomized	Recruiting	PC, GeC, OC, NSCLC, BC, BlC, MM, HNSCC,	Palliative	Locally advanced	400	200 mg	Safety	Part A: Pembrolizumab, DE Pexidartinib (PLX3397)	NA	NA	NA	Wainberg et al[50]
	(MK-3475/SCH 900475)						Metastatic			Efficacy (ORR; CR, PR)	Part B: RD Pexidartinib (PLX3397), Pembrolizumab
PD-L1	Durvalumab (MEDI4736)	1	Non-randomized	Recruiting	PC	Palliative	Metastatic	60	NA	Safety	Durvalumab, SBRT (Arm A)	NA	NA	NA	Duffy et al[31]
										Efficacy (ORR, PFS)	Tremelimumab, SBRT (Arm B)
										Tolerability	Durvalumab, Tremelimumab, SBRT (Arm C)
										PK
		1|2	NA	Recruiting	PC, NSCLS, mBC	Palliative	Metastatic	160	NA	Safety (AE, DLT)	Part 1: Durvalumab, DLT Ibrutinib	NA	NA	NA	Borazanci et al[74]
										Efficacy	Part 2: Durvalumab, RD Ibrutinib
										Tolerability
										RD
										PK

ORR: Overall response rate; DLT: Dose limiting toxicity; NA: Not available.